
    
      A total of 30 subjects will be randomly assigned to one of 3 different arms in order to
      evaluate the safety, tolerability and immunogenicity of a candidate vaccine, formulated with
      or without adjuvant, and the outcome compared to a placebo control group.

      For each active treatment group, 12 subjects will be injected twice with 10 Î¼g Flexyn2a
      candidate vaccine 4 weeks apart. A control group with 6 subjects will be injected following
      the same schedule with a placebo solution.
    
  